The role of academic institutions in the development of drugs for rare and neglected diseases

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 2, 2012, Pages 193-202

  Coles, L D ^a   Cloyd, J C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; ORPHAN DRUG;

ACT; ARTICLE; BUILDING; CAREER MOBILITY; CLINICAL RESEARCH; DRUG APPROVAL; DRUG INDICATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; FUNDING; GOVERNMENT; HEALTH CARE PLANNING; HUMAN; MEDICAL SOCIETY; MEDICAL STUDENT; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; RARE DISEASE; REIMBURSEMENT; SCIENTIST; SEIZURE; UNIVERSITY;

ACADEMIC MEDICAL CENTERS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MODELS, THEORETICAL; NEGLECTED DISEASES; ORPHAN DRUG PRODUCTION; RARE DISEASES; UNIVERSITIES;

EID: 84864116400     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.83     Document Type: Article

References (42)

1. Abbott, A. Bulgarian funding agency accused of poor practice. Nature 472, 19 (2011).
2. Braun, M.M., Farag-El-Massah, S., Xu, K. & Cote, T.R. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 9, 519-522 (2010).
3. S chieppati, A., Henter, J.I., Daina, E. & Aperia, A. Why rare diseases are an important medical and social issue. Lancet 371, 2039-2041 (2008). (Pubitemid 351799861)
4. Perraudin, F. Is it time we paid more attention to rare diseases? TIME, 21 August 2010.
5. S teven Burrill, G. Biotech 2011-Life Sciences: Looking Back to See Ahead, Burrill & Company, April 2011, 37 (Burrill & Company, San Francisco, CA, 2011).
6. A riyanchira, S. Global Markets for Orphan Drugs (BCC Research, Wellesley, MA, USA, 2010).
7. Orphan Drug Approvals Dramatically Up Relative to Non-Orphan Indications in 2011, February 1, 2012 posted by Frommer Lawrence & Haug on February 1, 2012, written by Pittman, S.B. (2012) 〈http://www.fdalawyersblog.com/2012/ 02/orphan-drug-approvals-dramatic.html〉.
8. Meekings, K.N., Williams, C.S. & Arrowsmith, J.E. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov. Today (2012); e-pub ahead of print.
9. Committee on Accelerating Rare Diseases Research and Orphan Product Development; Orphan Product Development; Institute of Medicine. Rare Diseases and Orphan Products: Accelerating Research and Development (eds. Field, M.J. & Boat, T.F.) (National Academies Press, Washington DC, 2011).
10. Lee, T. University of Minnesota ramps up effort to commercialize drugs. MEDCITY NEWS 〈www.medcitynews.com/2010/07/university-of-minnesotaramps-up- effort-to-commercialize-drugs/〉 (27 July 2010).
11. EURORDIS. About Rare Diseases 〈http://www.eurordis.org/about- rarediseases〉.
12. National Organization for Rare Disorders 〈http://rarediseases.org/ about〉.
13. T horat, C. et al. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis. Pediatrics 129, 516-521 (2012).
14. S asinowski, F. Quantum of effectiveness evidence in FDA's approval of orphan drugs. In Cataloguing FDA's Flexibility in Regulating Therapies for Persons with Rare Disorders. 238-263 (National Organization for Rare Disorders, Danbury, CT, 2011).
15. Bashaw, E.D. et al. Clinical pharmacology as a cornerstone of orphan drug development. Nat. Rev. Drug Discov. 10, 795-796 (2011).
16. Kriel, R.L., Cloyd, J.C., Hadsall, R.S., Carlson, A.M., Floren, K.L. & Jones-Saete, C.M. Home use of rectal diazepam for cluster and prolonged seizures: efficacy, adverse reactions, quality of life, and cost analysis. Pediatr. Neurol. 7, 13-17 (1991).
17. Dreifuss, F.E. et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N. Engl. J. Med. 338, 1869-1875 (1998). (Pubitemid 28287858)
18. Cloyd, J.C., Lalonde, R.L., Beniak, T.E. & Novack, G.D. A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam. Epilepsia 39, 520-526 (1998). (Pubitemid 28221809)
19. S ardana, D., Zhu, C., Zhang, M., Gudivada, R.C., Yang, L. & Jegga, A.G. Drug repositioning for orphan diseases. Brief. Bioinformatics 12, 346-356 (2011).
20. Padhy, B.M. & Gupta, Y.K. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J. Postgrad. Med. 57, 153-160 (2011).
21. Oprea, T.I. et al. Drug Repurposing from an Academic Perspective. Drug Discov. Today. Ther. Strateg. 8, 61-69 (2011).
22. Muthyala, R. Orphan/rare drug discovery through drug repositioning. Drug Discov. Today 8, 3-4 (2011).
23. Lussier, Y.A. & Chen, J.L. The emergence of genome-based drug repositioning. Sci. Transl. Med. 3, 96ps35 (2011).
24. Harrison, C. Signatures for drug repositioning. Nat. Rev. Genet. 12, 668 (2011).
25. Dolgin, E. Trial networks move beyond single-disease strategies. Nat. Med. 17, 1525 (2011).
26. S tevens, A.J., Jensen, J.J., Wyller, K., Kilgore, P.C., Chatterjee, S. & Rohrbaugh, M.L. The role of public-sector research in the discovery of drugs and vaccines. N. Engl. J. Med. 364, 535-541 (2011).
27. National Center for Advancing Translational Sciences. NCATS Pharmaceutical Collection 〈http://www.ncats.nih.gov/research/tools/ preclinical/npc/pharmaceutical-collection.html〉.
28. US Food and Drug Administration. A Valuable Resource for Drug Developers: The Rare Disease Repurposing Database (RDRD) 〈http://www. fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/ HowtoapplyforOrphanProductDesignation/ucm216147.htm〉.
29. Peng, X. University spin-offs: opportunity or challenge? Nat. Mater. 5, 923-925 (2006). (Pubitemid 44847482)
30. T he University of Notre Dame, The Center for Rare and Neglected Diseases 〈http://www.nd.edu/~crnd/index.html〉.
31. Boston Children's Hospital Manton Center for Orphan Disease Research 〈http://www.childrenshospital.org/cfapps/research/data-admin/Site2673/ mainpageS2673P0.html〉.
32. University of Minnesota Center for Orphan Drug Research 〈http://www. health.umn.edu/education/OrphanDrugs/index.htm〉.
33. Miller, W.P. et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood 118, 1971-1978 (2011).
34. Holmay, M., Coles, L., Mishra, U., Basso, L., Orchard, P.J., Cloyd, J.C. Pharmacokinetics of N-acetylcysteine as adjunctive therapy in hematopoietic stem cell transplantation for late-stage childhood cerebral adrenoleukodystrophy. Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, Atlanta, GA, June 2010.
35. Keck Graduate Institute, Center for Rare Disease Therapies 〈http://www.kgi. edu/faculty-and-research/kgi-centers/center-for-rare- disease-therapies.html〉.
36. NIH Clinical and Translational Science Awards 〈http://www.ncats.nih. gov/research/cts/ctsa/ctsa.html〉.
37. NIH National Center for Advancing Translational Sciences 〈http://www.ncats. nih.gov/research/cts/ctsa/ctsa.html〉.
38. NIH Chemical Genomics Center 〈http://www.ncats.nih.gov/research/ reengineering/ncgc.html〉.
39. T herapeutics for Rare and Neglected Diseases 〈http://www.ncats.nih. gov/research/rare-diseases/trnd/trnd.html〉.
40. Bridging Interventional Development Gaps 〈http://www.ncats.nih.gov/ research/reengineering/bridgs/bridgs.html〉.
41. Rare Diseases Clinical Research Network 〈http://rarediseasesnetwork. epi.usf. edu〉.
42. National Institute of General Medical Sciences. NIH Pharmacogenomics Research Network 〈http://www.nigms.nih.gov/Research/FeaturedPrograms/ PGRN〉.